Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMX-based oxygen delivery vehicles
- Development stage
- Unknown
- Lead developer
- Omniox
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
OMX-based oxygen delivery vehicles are novel biotherapeutics engineered to deliver oxygen specifically to severely hypoxic tissues. Unlike traditional hemoglobin (Hb)-based carriers, these agents are derived from the H-NOX (heme-nitric oxide/oxygen binding) protein family and do not scavenge nitric oxide in the vasculature. Their engineered O2 affinity ensures that they release their cargo only under pathologic hypoxic conditions, minimizing risks of systemic side effects or excessive blood oxygenation. Preclinical studies have demonstrated that administration of OMX improves metabolic and hemodynamic outcomes and increases survival in animal models of hemorrhagic shock and acute myocardial hypoxia. The technology is being developed for potential applications in trauma (hemorrhagic shock), cardiovascular disease (myocardial ischemia), stroke, cancer, and as a general blood substitute[1][2][3][4][5][7].
- Brand names
- OMX-CV
- Other names
- H-NOX-based oxygen carriernon-hemoglobin-based oxygen carrierOmniox-cardiovascular
02
Targets
H-NOX (Engineered Heme-Nitric Oxide/Oxygen binding protein)
Beyond the preview
Go deeper on OMX-based oxygen delivery vehicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMX-based oxygen delivery vehicles.